Sino Biopharm Reports Promising Early Data for PD-1/VEGF Bispecific Cancer Drug Licensed to Merck

Sino Biopharmaceutical’s subsidiary reported preliminary Phase 1/2 data for MK-2010/LM-299 in 112 heavily pretreated patients, showing a manageable safety profile with no treatment-related deaths and early efficacy in first-line NSCLC, including ORR of 55% at 20 mg/kg and 44% at 30 mg/kg. The globally licensed Merck asset supports the company’s oncology pipeline and strategic partnership value. The latest analyst view on HK:1177 remains Buy with a HK$8.70 price target.

Analysis

This read-through is more important for Merck than for Sino Biopharm: the data de-risks a new oncology platform that can credibly compete in the PD-1 plus anti-VEGF lane, but the real second-order effect is optionality on future combination regimens and label breadth. If the signal holds, the asset could become a backbone therapy in first-line lung and other high-incidence tumors, which matters because combination franchises tend to create durable pricing power and reduce reliance on any single checkpoint asset.

The market should not extrapolate too much from the headline response rates alone. In this space, the key question is whether the regimen preserves efficacy while improving tolerability enough to expand addressable patients versus existing VEGF/PD-1 combinations; the “manageable safety” profile is the bigger commercial catalyst than the ORR. For Merck, this could help defend its immuno-oncology moat if the platform becomes another partner-led pipeline filler, but it also raises competitive pressure on other large pharma pursuing similar bispecific or combo strategies.

The main risk is a multi-quarter gap between early signal and registrational clarity; most oncology assets with strong phase 1/2 data fade when randomized data introduce dilution from broader populations or less-selected sites. Near term, the share reaction should be modest because the announcement is scientific rather than financial, but over 6-18 months it could re-rate both companies if subsequent cohorts confirm dose consistency and differentiation versus incumbent regimens. The contrarian angle is that investors may be over-focusing on the China-origin story and underappreciating that the real value capture sits with the global licensee if development progress accelerates.

For Sino Biopharm, this is more of a pipeline-quality and partnership validation event than a direct earnings event, so any valuation upside should be bought on weakness rather than chased into strength. The stock’s low YTD move suggests the market is not pricing meaningful pipeline optionality; if additional clinical readouts land before year-end, this could become a sentiment-driven rerating rather than a fundamentals-driven one.

Key Decisions for Investors

• Long MRK vs. short a basket of large-cap pharma with weaker oncology pipelines over 3-6 months; this is a low-beta way to own asymmetric platform optionality if the bispecific story keeps maturing.
• Buy HK:1177 on pullbacks, not breakouts; use a 3-6 month horizon and treat this as a catalyst-trading position with upside tied to follow-on data rather than current earnings.
• Pair trade: long MRK / short a rival IO-heavy pharma name exposed to PD-1 saturation risk; the trade works if investors rotate toward companies with cleaner next-gen combo exposure.
• For higher convexity, consider MRK call spreads 6-12 months out to express confidence in development continuation while limiting downside if later data disappoint.
• If subsequent cohorts show no incremental efficacy beyond existing standards, cut Sino/Merck exposure quickly; the reversal risk is high once randomized differentiation fails to appear.